Literature DB >> 26823915

Differential proteomics analysis of mononuclear cells in cerebrospinal fluid of Parkinson's disease.

Lifei Xing1, Dongtao Wang2, Lihong Wang3, Wenjie Lan3, Suyue Pan4.   

Abstract

Parkinson's disease (PD) is one common neurodegenerative disease featured with degeneration of dopaminergic neurons in substantia nigra. Multiple factors participate in the pathogenesis and progression of PD. In this study, we investigated the proteomics profiles of mononuclear cells in cerebrospinal fluids from both PD patients and normal people, in order to explore the correlation between disease factors and PD. Cerebrospinal fluid samples were collected from both PD and normal people and were separated for mononuclear cells in vitro. Proteins were then extracted and separated by 2-dimensional gel electrophoresis. Proteins with differential expressions were identified by comparison to standard proteome expression profile map, followed by software and database analysis. In PD patients, there were 8 proteins with consistent expression profile and 16 proteins with differential expressions. Those differential proteins identified include cytoskeleton proteins (actin, myosin), signal transduction proteins (adenosine cyclase binding protein 1, calcium binding protein, talin) and anti-oxidation factor (thioredoxin peroxide reductase). PD patients had differential protein expressional profiles in the mononuclear cells of cerebrospinal fluids compared to normal people, suggesting the potential involvement of cytoskeleton and signal transduction proteins in apoptosis of neuronal apoptosis and PD pathogenesis.

Entities:  

Keywords:  Parkinson’s disease; cerebrospinal fluid; mononuclear cells; proteomics

Mesh:

Substances:

Year:  2015        PMID: 26823915      PMCID: PMC4713701     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  19 in total

Review 1.  On the development of plasma protein biomarkers.

Authors:  Silvia Surinova; Ralph Schiess; Ruth Hüttenhain; Ferdinando Cerciello; Bernd Wollscheid; Ruedi Aebersold
Journal:  J Proteome Res       Date:  2010-12-13       Impact factor: 4.466

2.  Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures.

Authors:  Andrew N Hoofnagle; Jessica O Becker; Michael N Oda; Giorgio Cavigiolio; Philip Mayer; Tomas Vaisar
Journal:  Clin Chem       Date:  2012-02-03       Impact factor: 8.327

Review 3.  Parkinson's disease: genetics and pathogenesis.

Authors:  Joshua M Shulman; Philip L De Jager; Mel B Feany
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

4.  Immune functions in Parkinson's disease.

Authors:  R J Marttila; J Eskola; M Päivärinta; U K Rinne
Journal:  Adv Neurol       Date:  1984

Review 5.  Biomarkers in Parkinson's disease (recent update).

Authors:  Sushil Sharma; Carolyn Seungyoun Moon; Azza Khogali; Ali Haidous; Anthony Chabenne; Comfort Ojo; Miriana Jelebinkov; Yousef Kurdi; Manuchair Ebadi
Journal:  Neurochem Int       Date:  2013-06-19       Impact factor: 3.921

Review 6.  Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease.

Authors:  W Michael Caudle; Theo K Bammler; Yvonne Lin; Sheng Pan; Jing Zhang
Journal:  Expert Rev Neurother       Date:  2010-06       Impact factor: 4.618

Review 7.  The pathology roadmap in Parkinson disease.

Authors:  D James Surmeier; David Sulzer
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 8.  A review of methods used to study cognitive deficits in Parkinson's disease.

Authors:  Abdul Qayyum Rana; Mohamed Sufian Masroor; Atif Saeed Khan
Journal:  Neurol Res       Date:  2013-01       Impact factor: 2.448

9.  Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.

Authors:  Kenneth Marek; Danna Jennings; Gilles Tamagnan; John Seibyl
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

Review 10.  Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.

Authors:  Manfred Gerlach; Walter Maetzler; Karl Broich; Harald Hampel; Lucas Rems; Torsten Reum; Peter Riederer; Albrecht Stöffler; Johannes Streffer; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-07-14       Impact factor: 3.575

View more
  1 in total

1.  From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms.

Authors:  Sara Redenšek; Vita Dolžan; Tanja Kunej
Journal:  OMICS       Date:  2018-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.